Biology and management of pancreatic cancer.
作者信息
Ghaneh Paula, Costello Eithne, Neoptolemos John P
机构信息
Division of Surgery and Oncology, University of Liverpool, Liverpool L69 3GA, UK.
出版信息
Gut. 2007 Aug;56(8):1134-52. doi: 10.1136/gut.2006.103333.
Abstract
摘要
相似文献
1
Biology and management of pancreatic cancer.
Gut. 2007 Aug;56(8):1134-52. doi: 10.1136/gut.2006.103333.
2
Molecular oncology in pancreatic cancer.
J Mol Med (Berl). 1996 Jun;74(6):313-20. doi: 10.1007/BF00207508.
3
Pancreatic carcinogenesis.
Pancreatology. 2008;8(2):110-25. doi: 10.1159/000123838. Epub 2008 Apr 1.
4
Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
Cancer Treat Rev. 2000 Feb;26(1):29-52. doi: 10.1053/ctrv.1999.0144.
5
[Molecular mechanism in pancreatic carcinogenesis: Ras gene].
Nihon Rinsho. 2006 Jan;64 Suppl 1:32-5.
6
Trials of gene therapy for pancreatic carcinoma.
Curr Gastroenterol Rep. 2005 Jun;7(3):165-9. doi: 10.1007/s11894-005-0028-7.
7
Signaling pathways in pancreatic cancer.
Cancer J. 2001 Jul-Aug;7(4):274-86.
8
Pancreatic cancer.
Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275. doi: 10.1067/mcn.2002.129579.
9
[Pancreatic cancer--diagnostic].
Dtsch Med Wochenschr. 2002 Nov 2;127(44):2326-9. doi: 10.1055/s-2002-35184.
10
[Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part I). Grupo Español de Consenso en Cáncer de Páncreas].
Med Clin (Barc). 2010 May 15;134(14):643-55. doi: 10.1016/j.medcli.2009.12.014. Epub 2010 Mar 26.
引用本文的文献
1
Palliative biliodigestive bypass for unresectable pancreatic malignancy at Kilimanjaro Christian medical centre: a retrospective cross-sectional study.
BMC Gastroenterol. 2025 Feb 21;25(1):103. doi: 10.1186/s12876-025-03683-8.
2
Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma.
Curr Issues Mol Biol. 2025 Jan 3;47(1):27. doi: 10.3390/cimb47010027.
3
Minimally invasive versus open pancreatoduodenectomy in benign, premalignant, and malignant disease.
Cochrane Database Syst Rev. 2024 Jul 26;7(7):CD014017. doi: 10.1002/14651858.CD014017.
4
Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia.
BMC Cancer. 2024 Apr 4;24(1):414. doi: 10.1186/s12885-024-12104-0.
5
Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.
Int J Mol Sci. 2023 Mar 7;24(6):5113. doi: 10.3390/ijms24065113.
6
An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling.
Front Immunol. 2022 Jul 28;13:961457. doi: 10.3389/fimmu.2022.961457. eCollection 2022.
7
The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers.
Front Immunol. 2022 Feb 24;13:844001. doi: 10.3389/fimmu.2022.844001. eCollection 2022.
8
Identification of New Regulators of Pancreatic Cancer Cell Sensitivity to Oxaliplatin and Cisplatin.
Molecules. 2022 Feb 14;27(4):1289. doi: 10.3390/molecules27041289.
9
A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract.
Med Sci Monit. 2022 Feb 5;28:e935348. doi: 10.12659/MSM.935348.
10
Employing Novel Porcine Models of Subcutaneous Pancreatic Cancer to Evaluate Oncological Therapies.
Methods Mol Biol. 2022;2394:883-895. doi: 10.1007/978-1-0716-1811-0_47.
本文引用的文献
1
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.
Arch Surg. 2008 Jan;143(1):75-83; discussion 83. doi: 10.1001/archsurg.2007.17.
2
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
J Clin Oncol. 2007 Jun 20;25(18):2607-15. doi: 10.1200/JCO.2006.09.2551.
3
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
J Clin Oncol. 2007 Jun 1;25(16):2212-7. doi: 10.1200/JCO.2006.09.0886.
4
Palladin mutation causes familial pancreatic cancer: absence in European families.
PLoS Med. 2007 Apr;4(4):e164. doi: 10.1371/journal.pmed.0040164.
5
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23.
6
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.
Br J Cancer. 2007 Apr 23;96(8):1183-90. doi: 10.1038/sj.bjc.6603719. Epub 2007 Apr 3.
7
Identification of pancreatic cancer stem cells.
Cancer Res. 2007 Feb 1;67(3):1030-7. doi: 10.1158/0008-5472.CAN-06-2030.
8
Stromal biology of pancreatic cancer.
J Cell Biochem. 2007 Jul 1;101(4):887-907. doi: 10.1002/jcb.21209.
9
Methionine and vitamin B6 intake and risk of pancreatic cancer: a prospective study of Swedish women and men.
Gastroenterology. 2007 Jan;132(1):113-8. doi: 10.1053/j.gastro.2006.10.017. Epub 2006 Oct 12.
10
Cancer statistics, 2007.
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
Zotero 插件